A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Not yet recruitingNCT07205796
Shenzhen Shenxin Biotechnology Co., LtdHerpes Zoster
Start: 2026-05-01End: 2027-12-30Target: 480Updated: 2025-10-07